See which stocks are pulling investors into the conversation, what the crowd is saying, and whether the attention is broad or concentrated.
Top stocks by X chatter · rolling 3-day window
Hims & Hers Health reportedly raised full-year revenue guidance to $3.1-3.3B and posted 38% Q2 growth, yet the stock dropped roughly 9-14% post-earnings due to an $86.3M net loss and ongoing FTC scrutiny.
Research →Takeda reportedly received FDA approval for MIMRYLO (rusfertide), a first-in-class hepcidin mimetic for treating erythrocytosis in adults with polycythemia vera. The clearance marks a potential shift in the treatment paradigm for the condition.
Research →Open any ticker to investigate the catalyst, price action, filings, earnings, news, positioning, and risks.